W Christopher Ehmann
Overview
Explore the profile of W Christopher Ehmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pu J, Berger K, Zheng C, Do N, Claxton D, Ehmann W, et al.
Front Oncol
. 2024 Dec;
14:1449401.
PMID: 39737396
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT01439750.
2.
Jia B, Zhao C, Minagawa K, Shike H, Claxton D, Ehmann W, et al.
J Immunol
. 2023 Sep;
211(9):1426-1437.
PMID: 37712758
Allogeneic hematopoietic stem cell transplantation (alloSCT) is, in many clinical settings, the only curative treatment for acute myeloid leukemia (AML). The clinical benefit of alloSCT greatly relies on the graft-versus-leukemia...
3.
Zhou H, Jia B, Annageldiyev C, Minagawa K, Zhao C, Mineishi S, et al.
Front Immunol
. 2023 Jul;
14:1169144.
PMID: 37457737
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Novel effective treatment is an urgent unmet need. Immunotherapy targeting T cell exhaustion by blocking inhibitory pathways, such...
4.
Potiaumpai M, Schmitz K, Mineishi S, Naik S, Wirk B, Rakszawski K, et al.
BMJ Open
. 2023 Jan;
13(1):e066841.
PMID: 36657760
Introduction: Haematopoietic stem cell transplant (HSCT) in adults is an intensive medical procedure for a variety of haematological malignancies. Although there is a large body of evidence demonstrating the negative...
5.
Pizzola C, Cioccio J, Rakszawski K, Nickolich M, Ehmann W, Rybka W, et al.
Bone Marrow Transplant
. 2022 Sep;
57(11):1743-1745.
PMID: 36097041
No abstract available.
6.
Jia B, Zhao C, Bayerl M, Shike H, Claxton D, Ehmann W, et al.
J Leukoc Biol
. 2021 May;
111(2):427-437.
PMID: 34057741
The prognosis for acute myeloid leukemia (AML) relapse post allogeneic hematopoietic stem cell transplantation (alloSCT) is dismal. Novel effective treatment is urgently needed. Clinical benefit of alloSCT greatly relies on...
7.
Zheng H, Mineishi S, Claxton D, Zhu J, Zhao C, Jia B, et al.
Am J Hematol
. 2020 Nov;
96(2):E46-E50.
PMID: 33146922
No abstract available.
8.
Zhao C, Jia B, Wang M, Schell T, Claxton D, Ehmann W, et al.
Br J Haematol
. 2019 Oct;
188(5):674-684.
PMID: 31573077
Decitabine is a DNA-hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the...
9.
Jia B, Zhao C, Rakszawski K, Claxton D, Ehmann W, Rybka W, et al.
Cancer Res
. 2019 Feb;
79(7):1635-1645.
PMID: 30709927
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Immunotherapy targeting inhibitory pathways to unleash the antileukemia T-cell response is a promising strategy for the treatment of...
10.
Wang L, Jia B, Claxton D, Ehmann W, Rybka W, Mineishi S, et al.
Oncoimmunology
. 2018 Sep;
7(9):e1469594.
PMID: 30228937
Treatment of acute myeloid leukemia (AML) remains challenging. Enhancement of anti-tumor responses by blocking negative immune regulators is a promising strategy for novel effective leukemia therapeutics. V-domain Ig suppressor of...